pharmaphorum

JUNE 15, 2021

NHS England will provide artificial pancreas devices to 1,000 type 1 diabetes patients as part of a pilot study of the technology, according to chief executive Sir Simon Stevens. A decision is expected in early 2022. The post Artificial pancreas will be piloted in 1,000 diabetics, says NHS CEO appeared first on.

Diabetes 131

Diabetes Communication 131

European Pharmaceutical Review

SEPTEMBER 8, 2023

Eli Lilly ’s Mounjaro (tirzepatide), has been recommended to treat poorly controlled type 2 diabetes in adults alongside diet and exercise. The US Food and Drug Administration (FDA) first approved tirzepatide for type 2 diabetes in May 2022. The European Commission approved the injectable treatment in September 2022.

Diabetes 105

Diabetes 105

Express Pharma

NOVEMBER 4, 2024

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk’s diabetes drug, liraglutide, to its platform in 2025. It results in less weight loss on average than Novo’s newer in-demand Wegovy, which launched in 2020 and was approved in 2022 for adolescents aged 12 and older.

Compounding 105

Compounding Diabetes 105

European Pharmaceutical Review

OCTOBER 18, 2023

TZIELD (teplizumab-mzwv) has demonstrated TZIELD’s potential to slow disease progression in newly diagnosed children and adolescents with Stage 3 type 1 diabetes. About TZIELD The CD3-directed monoclonal antibody treatment is the first and only disease modifying therapy in type 1 diabetes, according to Sanofi.

Diabetes 111

Diabetes 111

Express Pharma

NOVEMBER 7, 2023

The type 2 diabetes (T2D) landscape has historically been dominated by insulin receptor (IR) targeting drugs. This condition disrupts glucose metabolism, resulting in high blood glucose levels and a variety of effects thereafter, such as an increased risk of stroke and diabetic neuropathy. IR’s role in T2D is well-defined.

Diabetes 111

Diabetes 111

Express Pharma

APRIL 27, 2023

Cipla holds a prominent position in the top five therapy areas in India, except for the anti-diabetes and gastrointestinal segment. Against this backdrop, the Indian pharma major is constantly partnering with multinational companies to get access to an innovative portfolio with a focus on diabetes, says GlobalData.

Diabetes 93

Diabetes 93

European Pharmaceutical Review

DECEMBER 7, 2022

percent when used alongside other baseline treatments (diet, exercise, metformin and/or insulin), compared with placebo in a Phase III clinical trial of children and adolescents aged 10-17 years with type 2 diabetes. What is your opinion on Jardiance ® (empagliflozin) becoming another option for managing type 2 diabetes?

Diabetes 98

Diabetes Medical Schools 98

Eye on FDA

JANUARY 26, 2022

FDA’s Office of Prescription Drug Promotion (OPDP) issued the first regulatory action letter for 2022. That said, the last two letters – the final one of 2021 and the first of 2022 both went to the same company – Lilly. This one has some notable characteristics.

Communication 108

Communication Diabetes 108

Express Pharma

JUNE 11, 2023

billion compared to the last 12-month average (May 2022 to April 2023) of 79 deals worth $17 billion. per cent in May 2023, compared to May 2022 The healthcare industry reported 125 venture capital (VC) deals worth $2.7 billion in May 2023, compared to the last 12-month average (May 2022 to April 2023) of 138 deals worth $2.6

Diabetes 128

Diabetes 128

pharmaphorum

NOVEMBER 20, 2020

Just over a year after its first phase 3 trial of its Engensis gene therapy for painful diabetic peripheral neuropathy (DPN) bombed, Helixmith has started dosing patients in a new study. It is due to generate results in December 2021, which could lead to filings in 2022.

Diabetes 98

Diabetes 98

Pharmaceutical Technology

APRIL 12, 2023

Clinical-stage biotechnology firm LyGenesis has formed a joint research collaboration with Imagine Pharma to develop new cell therapies for type 1 diabetes (T1D). In June 2022, the company discovered T1D AIPCs, a critical component to treat T1D through autologous cell transplantation.

Diabetes 98

Diabetes 98

Pharmaceutical Technology

JANUARY 10, 2023

On November 17, 2022, the FDA approved Provention Bio’s Tzield (teplizumab) , making it the first and only treatment to delay the onset of type 1 diabetes (T1D). Tzield’s approval brings the opportunity to explore how the drug can advance diabetes education, treatment, and management. “We Equity in early-stage testing.

Diabetes 98

Diabetes Immunization Immunity Communication 98

ALiEM - Pharm Pearls

OCTOBER 20, 2023

A 50-year-old Caucasian female with a history of hypertension, coronary artery disease, and insulin-dependent diabetes mellitus presents to the emergency department with a complaint of painful sores on the top of her left foot. It may be equally common in patients without diabetes, hence was renamed without the term “diabeticorum”.

Diabetes 161

Diabetes 161

Express Pharma

MAY 29, 2023

Hefei Tianhui Biotechnology (HTIT) has recently submitted a marketing authorisation application (MAA) in China for the world’s first oral insulin for type 2 diabetes (T2D). The number of diagnosed prevalent cases of type 2 diabetes in China is estimated to grow at a CAGR of 2.21 million in 2022 to 63.3 per cent from 57.4

Diabetes 94

Diabetes 94

pharmaphorum

JULY 29, 2021

The US regulator will review the drug for both neovascular or ‘wet’ age-related macular degeneration (AMD) and diabetic macular oedema (DME), as well as diabetic retinopathy under a standard review. The post FDA starts review of Roche’s eye disease drug, setting up 2022 verdict appeared first on.

Diabetes 98

Diabetes Biosimilars 98

Med Ed 101

JANUARY 12, 2022

The American Diabetes Association released their 2022 Diabetes Guidelines update. The patient population that I work with the most is those who have Type 2 diabetes. The post 2022 Diabetes Guidelines – Pharmacotherapy Essentials appeared first on Med Ed 101.

Diabetes 40

Diabetes 40

Pharma Pathway

SEPTEMBER 16, 2022

Torrent Pharmaceuticals- Walk-Ins for Bioanalytical/ Pharmacokinetic On 17th Sept’ 2022. Torrent Pharma enjoys dominance in the niche therapeutic areas like, cardiovascular and central nervous system, gastro-intestinal, pain management and oral anti-diabetic segments. Date: 17th Sept’ 2022. Job Description. Contact Details: .

Diabetes 83

Diabetes Hospitals 83

Med Ed 101

FEBRUARY 20, 2022

I recently blogged about my thoughts on the new diabetes guidelines. He’s put together a phenomenal resource with his 2022 Diabetes Guidelines Cheat Sheet. The post Free Download – 2022 Diabetes Guidelines Cheat Sheet appeared first on Med Ed 101. Simply signing up for a new […].

Diabetes 40

Diabetes 40

STAT

AUGUST 5, 2024

All doses of Eli Lilly’s weight loss drug Zepbound and diabetes drug Mounjaro are now available , Reuters notes, citing an updated list from the U.S. Lilly’s Mounjaro has been on the FDA shortages list since late 2022, while Zepbound was added to the list in April this year. Food and Drug Administration.

Diabetes 206

Diabetes 206

Pharma Pathway

SEPTEMBER 17, 2022

Torrent Pharmaceuticals- Walk-Ins for ADL/ F&D/ Technology Transfer On 18th Sept’ 2022. Torrent Pharma enjoys dominance in the niche therapeutic areas like, cardiovascular and central nervous system, gastro-intestinal, pain management and oral anti-diabetic segments. Date: 18th Sept’ 2022. Job Description.

Diabetes 82

Diabetes 82

Pharma Pathway

DECEMBER 3, 2022

Torrent Pharmaceutical Limited- Walk-Ins for M.Pharm/ M.Sc/ B.Pharm/ B.Sc/ ITI in QA/ QC/ Tablet/ Packaging Departments On 4th Dec’ 2022. Torrent Pharma enjoys dominance in the niche therapeutic areas like, cardiovascular and central nervous system, gastro-intestinal, pain management and oral anti-diabetic segments.

Packaging 77

Packaging Diabetes Hospitals 77

Express Pharma

OCTOBER 18, 2023

It must be taken once daily, under prescription, to improve glycemic control in patients with Type 2 diabetes. According to IQVIA sales data for the 12‐month period ending August 2023 (MAT August 2023), the market for oral anti‐diabetic drugs in India is estimated to be Rs 12,522 crores, with an annual growth of 6.5 per cent.

Diabetes 105

Diabetes 105

Pharmaceutical Technology

NOVEMBER 25, 2022

In recent months, Wegovy (semaglutide), indicated for obesity, has been subjected to widespread supply shortages due to high demand, in addition to manufacturer production problems, with Novo Nordisk intending to relaunch Wegovy by the end of 2022.

Diabetes 111

Diabetes Labelling 111

Express Pharma

JANUARY 14, 2025

Products in this category are often prescribed by practitioners, such as nephrologists for renal care or diabetologists for managing diabetes. billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.3 billion in 2023 and is expected to grow at a CAGR of 8.4 per cent from 2024 to 2030.

Diabetes 105

Diabetes Compounding 105

pharmaphorum

NOVEMBER 26, 2021

The VBP for insulin – which applies to supplies destined for hospitals in China – is expected to be implemented during the first half of 2022, according to Novo Nordisk. billion) of diabetes drugs there in the first nine months of this year, 75% of which was insulin. billion in 2020.

Diabetes 59

Diabetes Hospitals 59

pharmaphorum

JANUARY 24, 2023

Eli Lilly is leaving nothing to chance when it comes to making the most of its fast-growing diabetes therapy Mounjaro – it is investing another $450 million at a facility in North Carolina that will make the drug. billion in the third quarter of 2022 – on its way to peak sales that some analysts predict could reach more than $3 billion.

Diabetes 97

Diabetes Packaging 97

Pharmacy Times

JULY 15, 2022

The FDA approved tirzepatide for the treatment of type 2 diabetes on May 13, 2022.

Diabetes 49

Diabetes 49

pharmaphorum

MARCH 31, 2022

More than 250,000 people living with type 1 diabetes in the UK will be offered real-time continuous glucose monitoring (CGM) technology, reducing their reliance on fingerprick testing, according to NICE. At the moment, flash CGM has been rolled out to around half of patients with type 1 diabetes by NHS England. Exciting news!

Diabetes 52

Diabetes 52

European Pharmaceutical Review

AUGUST 20, 2024

The GIP and GLP-1 receptor agonist was evaluated over 176-weeks compared to placebo in adults with pre-diabetes and obesity or overweight. The aim of the study was to assess its efficacy and safety for long-term weight management and for delaying the participants progression to diabetes. Overall, tirzepatide facilitated a 22.9

Diabetes 52

Diabetes 52

pharmaphorum

MAY 21, 2021

Eli Lilly has scored five out of five with its phase 3 trials of type 2 diabetes candidate tirzepatide, setting up regulatory filings for a drug that the drugmaker thinks could be the lynchpin of its franchise in the coming years. .

Diabetes 52

Diabetes 52

Viseven

MARCH 27, 2023

This company specializes in biopharmaceuticals, diabetes care, obesity care, and other severe chronic diseases. The partnership aims to redesign healthcare professionals’ access and use of critical information about diabetes care. Interested in building your own Digital Content Factory? Let us know!

Communication 52

Communication Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

ALiEM - Pharm Pearls

SEPTEMBER 25, 2023

66 year-old-male with a history of type 2 diabetes and hypertension presented as a transfer for rapid progression of lower extremity pain, swelling, and blue-purple discoloration of the entire limb with concern for a possible necrotizing infection. 2022 Oct 3. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. Ann Vasc Dis.

Medical Schools 152

Medical Schools Diabetes 152

pharmaphorum

DECEMBER 21, 2022

Sosei Heptares’ longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for diabetes and obesity that will try to take on established rivals from Novo Nordisk and Eli Lilly. The post Sosei nets $10m Pfizer milestone as diabetes/obesity drug starts phase 2 appeared first on.

Diabetes 52

Diabetes Compounding 52

ALiEM - Pharm Pearls

OCTOBER 30, 2024

Last Words Substance use disorders (SUD) are similar to other chronic relapsing medical conditions such as diabetes mellitus, congestive heart failure/cardiomyopathy, chronic obstructive pulmonary disorder, and cancer. Drug Checking Quarterly Report (Q3 2022). 2022; 06/26/2023. 2022 May;14(5). 2011 Dec;6:1-4.

HIV Treatment and Prevention Agents 161

HIV Treatment and Prevention Agents Inpatient Hospitals Diabetes 161

Safe Biologics

MARCH 5, 2025

On February 22nd, the US Food and Drug Administration (FDA) announced the resulution of a years-long shortage of semaglutide, the key ingredient in popular GLP-1 weight loss and diabetes medications Ozempic amd Wegovy. Both drugs have been on the FDAs drug shortage list since 2022.

Compounding Pharmacies 130

Compounding Pharmacies Compounding Diabetes 130

National Association of Boards of Pharmacy

DECEMBER 13, 2023

Injectable diabetes medications including semaglutide, namely Wegovy and Ozempic, have been in shortage since 2022 , limiting patient access to the drug across the nation. The post Diabetes Drug Shortages and Fake Ozempic appeared first on National Association of Boards of Pharmacy.

Diabetes 56

Diabetes Compounding Pharmacies Compounding Online Pharmacies 56

Express Pharma

SEPTEMBER 20, 2023

billion for the 12 months ending December 31, 2022, according to IQVIA. It is highly similar to the reference product Eylea (aflibercept). Data shows that YESAFILI has comparable quality, safety, and efficacy to Eylea. Aflibercept had EU brand sales of approximately $1.8

Biosimilars 105

Biosimilars Diabetes 105